Business Description
TNF Pharmaceuticals Inc
NAICS : 541713
SIC : 2833
ISIN : US62856X1028
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 591.22 | |||||
Equity-to-Asset | 0.71 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -16.6 | |||||
3-Year EPS without NRI Growth Rate | -19.4 | |||||
3-Year FCF Growth Rate | -30.7 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
14-Day RSI | 26.47 | |||||
12-1 Month Momentum % | -65 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.72 | |||||
Quick Ratio | 1.72 | |||||
Cash Ratio | 1.52 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.7 | |||||
Shareholder Yield % | 2.49 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -209.15 | |||||
ROA % | -113.08 | |||||
ROIC % | -86.25 | |||||
ROC (Joel Greenblatt) % | -26223.5 | |||||
ROCE % | -73.73 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.19 | |||||
Price-to-Tangible-Book | 0.5 | |||||
EV-to-EBIT | 0.59 | |||||
EV-to-EBITDA | 0.59 | |||||
EV-to-FCF | 0.67 | |||||
Price-to-Net-Current-Asset-Value | 0.67 | |||||
Price-to-Net-Cash | 0.84 | |||||
Earnings Yield (Greenblatt) % | 169.49 | |||||
FCF Yield % | -294.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
TNF Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -12.744 | ||
Beta | 2.11 | ||
Volatility % | 55.89 | ||
14-Day RSI | 26.47 | ||
14-Day ATR (€) | 0.000007 | ||
20-Day SMA (€) | 1.89 | ||
12-1 Month Momentum % | -65 | ||
52-Week Range (€) | 1.89 - 5.52 | ||
Shares Outstanding (Mil) | 2.76 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
TNF Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
TNF Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
TNF Pharmaceuticals Inc Frequently Asked Questions
What is TNF Pharmaceuticals Inc(FRA:DQS0)'s stock price today?
When is next earnings date of TNF Pharmaceuticals Inc(FRA:DQS0)?
Does TNF Pharmaceuticals Inc(FRA:DQS0) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |